Christoph E. Heilig

This study uses pan-cancer phosphoproteomics to identify therapeutic targets and improve precision oncology by analyzing 1,998 tumor samples and developing new scores for kinase activity and immune response.

This study develops an ex vivo drug sensitivity testing platform for rare solid tumors and finds that high in vitro sensitivity correlates with clinical benefit and progression-free survival.

The paper introduces Knowledge Connector, a decision support system that integrates multiomics data with clinical information to aid in precision oncology decision-making.

ZygosityPredictor evaluates the number of gene copies affected by mutations in sequencing data, providing confidence measures for precision oncology applications.